ASCEND Blend Benefits: What the Research on Each Component Shows

The honest summary of the table: one component with real human trials, two with hormone-level studies, one with animal data only, and nothing on the combination.

ASCEND is four peptides in one vial, all aimed at the growth hormone axis. The pituitary releases growth hormone in pulses when it receives two signals at once: GHRH, and a ghrelin-receptor signal. CJC-1295 and tesamorelin both supply the first; ipamorelin supplies the second. Growth hormone does most of its work by prompting the liver to make IGF-1, and IGF-1 LR3 adds a small amount of that downstream signal directly. Pepti's vial holds 6 mg CJC-1295, 12 mg ipamorelin, 10 mg tesamorelin and 1 mg IGF-1 LR3, so by mass it is a secretagogue preparation with a small direct IGF-1 component. It is not growth hormone, not a weight-loss medication and not an anabolic steroid. The rationale, acting at three points on one axis with a single bedtime injection, is a rationale, not a finding.

What the research describes. This is tesamorelin's territory and the best evidence in the blend. The 2007 New England Journal of Medicine trial randomised 412 people with HIV and abdominal fat accumulation to daily tesamorelin 2 mg or placebo for 26 weeks: visceral fat on CT fell on treatment and rose on placebo, triglycerides fell, and glycaemic measures did not differ. A 2010 pooled analysis of two phase 3 trials covering 806 randomised patients reported the same pattern, no significant change in subcutaneous fat, and visceral fat returning toward baseline in those switched to placebo. Outside HIV, a 2012 trial randomised 60 abdominally obese adults with reduced growth hormone secretion to tesamorelin or placebo for 12 months and reported a selective reduction in visceral fat with no change in glucose measures.

Evidence type. Human randomised trials.

What it means for ASCEND. Every trial used a fixed daily dose of 1 or 2 mg. ASCEND delivers 0.5 mg five nights a week, alongside three other peptides, so the trial results describe tesamorelin at its studied doses, not ASCEND. The approved tesamorelin product's label also says it is not indicated for weight-loss management because its effect on weight is neutral; the measured change was in fat distribution, not on the scale. And the effect did not persist on its own after stopping. If visceral fat is the whole goal, tesamorelin alone is the component with the evidence; see tesamorelin benefits.

What the research describes. The human data on CJC-1295 is two 2006 studies in the Journal of Clinical Endocrinology and Metabolism, both of the DAC form in healthy adults. The first reported dose-dependent increases in growth hormone and IGF-1 that persisted for days after a single injection; the second sampled blood every ten minutes and reported that the pituitary's pulsatile pattern was preserved, with more growth hormone per pulse rather than a flat elevation. For ipamorelin, a 1999 paper in Pharmaceutical Research modelled the growth hormone response to intravenous ipamorelin in volunteers and reported dose-dependent release. In the 2007 tesamorelin trial, IGF-1 rose by 81 percent over 26 weeks.

Evidence type. Human, measuring hormone levels.

What it means. These studies establish that the secretagogues raise growth hormone and IGF-1 in people. They do not establish that higher levels change body composition, recovery or sleep in healthy adults, because none measured those. The CJC-1295 studies used the DAC form; ASCEND contains the form without DAC, dosed nightly. A rise in IGF-1 confirms a hormonal response; it is not a result in itself.

What the research describes. The 1998 characterisation paper in the European Journal of Endocrinology reported that in animal models ipamorelin released growth hormone with potency similar to GHRP-6 but did not raise ACTH, cortisol or prolactin at doses well above the releasing dose.

Evidence type. Animal.

What it means. That selectivity is why ipamorelin is the ghrelin-receptor agonist used in prescribing blends. It is a pharmacology finding about what ipamorelin avoids, not a benefit a person would notice. More in ipamorelin benefits.

What the research describes. This is the reason IGF-1 LR3 is in the vial. A 1992 paper in the Biochemical Journal reported that IGF-1 and, more so, modified variants including LR3 improved nitrogen balance and body-weight gain in rats made catabolic with dexamethasone. A 1995 paper in the Journal of Endocrinology infused LR3 IGF-1 into guinea pigs and reported organ growth, while the animals' own IGF-1, IGF-2 and binding proteins fell.

Evidence type. Animal only. There are essentially no published human clinical studies of IGF-1 LR3.

What it means. The animals in those studies were in a catabolic state induced by steroids, which is not a healthy adult training in a gym. And the guinea pig finding cuts both ways: supplying IGF-1 from outside turned down the body's own output. No study has measured what adding IGF-1 LR3 to three secretagogues does to the feedback loop they depend on. The muscle findings for IGF-1 are animal, and the tesamorelin trials did not measure muscle size or strength. See what is IGF-1 LR3.

What the research describes. Nothing directly. The rationale is physiological: the largest growth hormone pulse of the day occurs during slow-wave sleep, and a 2000 study in JAMA found slow-wave sleep and growth hormone secretion declining together in healthy men from early adulthood. That is why ASCEND is dosed at bedtime.

What patients report. People frequently report deeper sleep on secretagogues. That is a reported pattern, not a trial endpoint.

Evidence type. None direct. No published trial of any component, let alone the blend, has sleep as an endpoint. Peptides for sleep covers the wider picture.

What the research describes. Nothing directly. Recovery between training sessions is inferred from what growth hormone and IGF-1 do, not from any trial of these peptides. Prescribers describe some people reporting shorter recovery and easing stiffness; others notice nothing, which is normal.

Evidence type. None direct. No trial of any component has recovery as an endpoint.

What the research describes. Animal work on ipamorelin reports increased longitudinal bone growth and bone mineral content in rats.

Evidence type. Animal.

Strength. Rat studies only, of growing bone. Nothing in people, and nothing on ASCEND.

The case for a four-peptide blend is that two release signals converge on one pulse and a small direct IGF-1 signal adds to it. That axis logic is reasonable physiology. But no study has compared ASCEND with any of its components, or confirmed that the four act as described when injected together. "Four peptides" is not evidence of four times the benefit; it is four sets of considerations in one vial, with a fixed ratio that cannot be adjusted per component.

• That ASCEND changes muscle size, strength or scale weight in humans.
• That it improves sleep or recovery. Neither has been a trial endpoint for any component.
• Results at ASCEND's doses, or from the combination.
• An effect size or a timeline in humans. Anything said about "results in X weeks" is clinical experience, not trial data.
• Long-term safety over years of continuous use.
• Efficacy for any condition as an approved treatment. ASCEND is not approved for anything; tesamorelin's approval belongs to a different product at a different dose for a specific population.

IGF-1 promotes the growth and survival of cells generally, so a personal or family history of cancer is treated as a reason not to use this blend. Diabetes, a tendency to low blood sugar, or insulin and other glucose-lowering medications are raised at intake. The full picture is in ASCEND blend side effects.

Every price is all-in, covering medication, physician review, refill management and shipping, with no separate membership fee. Pepti is cash-pay and does not bill insurance. Vials are multi-dose solutions shipped ready to use, refrigerated with ice packs, with sterile syringes and alcohol prep pads. Refills run every 28 days, one vial per fill. Your physician sets your directions after reviewing your intake, and they are printed on the vial. Defaulting to the fullest formula is a common mistake with a four-component blend; CJC-1295 / Ipamorelin benefits and what is TITAN cover the simpler options.

ASCEND cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration. The prescription route:

1. Complete a free online intake covering your history, medications, blood sugar, cancer and family history, and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with your directions printed on the vial.
5. Your physician stays reachable for questions and side effects.

Pepti prescribes ASCEND in every state except Oklahoma, plus DC